NVO Price Prediction Next Week
Based on the provided data and recent market movements, here's a comprehensive analysis for NVO's price prediction for next week:
Technical Analysis
The stock has shown significant weakness, with RSI at 27.38 indicating oversold conditions. The stock is trading below both its 20-day moving average ($87.16) and 200-day moving average ($122.15), suggesting a strong downtrend. The MACD reading of -5.67 confirms the bearish momentum.
News Impact Analysis Several major news events are affecting NVO's price:
Medicare Price Negotiations: The inclusion of Wegovy in Medicare price negotiations for 2027 has created uncertainty. While analysts expect limited impact due to existing discounts, this could affect about 30% of net pricing by 2027.
JPMorgan Healthcare Conference: The conference highlighted strong potential for GLP-1 drugs, with analysts estimating the anti-obesity medication market could grow to $100 billion by decade's end. However, supply shortages remain a concern.
Recent Stock Performance: NVO experienced a significant drop last week, falling 8.89% after Ozempic and Wegovy were included in Medicare drug price negotiations.
Price Prediction for Next Week Based on technical indicators and news sentiment:
Expected price range: $76.50 - $82.00
- Support levels: $77.21 (Fibonacci S2)
- Resistance levels: $83.40 (Fibonacci pivot)
Trading Recommendation SELL with the following rationale:
- Bearish technical indicators with stock below key moving averages
- Negative news sentiment around Medicare negotiations
- Continued downward momentum indicated by MACD
- Stock experiencing institutional selling pressure
Target entry: Current market price ($78.81) Stop loss: $82.50 (above Fibonacci pivot) Price target: $76.50
The stock is likely to continue its downward trend next week due to ongoing concerns about drug pricing negotiations and technical weakness, despite the long-term positive outlook for GLP-1 drugs.
NVO Similar Chart Price Prediction
The price of NVO is predicted to go up 7.5%, based on the high correlation periods with MYND. The similarity of these two price pattern on the periods is 99.24%.
NVO
MYND
Up: 7.5%Similarity: 99.24%
NVO Stock Forecast & Prediction For Years 2025, 2026, 2027, 2028, 2029 and 2030
Year
NVO Price Forecast($)
Potential Return(%)
2025
87.250
-0.460
2026
120.000
36.910
2027
120.000
36.910
2028
140.000
59.730
2029
140.000
64.650
2030
150.000
76.410
What is NVO stock price prediction 2025 ?
What is NVO stock price prediction 2026 ?
What is NVO stock price prediction 2027 ?
What is NVO stock price prediction 2028 ?
What is NVO stock price prediction 2029 ?
What is NVO stock price prediction 2030 ?
NVO Revenue Forecast
NVO EPS Forecast
NVO FAQs
What is bull’s view on NVO?
What is bear's view on NVO?
What is NVO revenue forecast for next quarter？
NVO VS S&P500
Novo's new obesity therapy Wegovy is significantly expanding the obesity treatment market given its strong efficacy and is poised to remain a key drug in the market until patent expiration in 2032.
With a solid portfolio of GLP-1 products, including injectable Ozempic and oral Rybelsus, Novo is well positioned to defend its formidable diabetes market share.
Semaglutide is also being studied in areas including liver disease (NASH) and Alzheimer's, and Novo could achieve a strong share in these nascent markets.
NVO Analyst's Forecast
Evan David Seigerman
BMO Capital
Buy
Price Target
$160 → $156
Upside
+31.93%
BMO Capital analyst Evan Seigerman lowered the firm's price target on Novo Nordisk to $156 from $160 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results in BioPharma. Looking at script growth for Ozempic and Wegovy from Q2, the firm sees 4% and 24% growth, respectively, but while growth continues to be impressive, sell-side estimates may now be catching up to this growth, the analyst tells investors in a research note. Novo's Victoza scripts have declined nearly 50% from Q2 however as patients and providers transition to more efficacious agents Mounjaro / Ozempic, the firm added.